The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels

Journal of the American College of Cardiology

Volumn 69, Issue 15, 2017, Pages 1952-1967

  Paneni, Francesco ^a,b   Diaz Cañestro, Candela ^a   Libby, Peter ^c   Lüscher, Thomas F ^a,b   Camici, Giovanni G ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

arterial stiffness; endothelium; epigenetics; stem cells

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; KLOTHO PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND;

AGING; ANGIOGENESIS; ARTERIAL STIFFNESS; AUTOTRANSPLANTATION; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHROMATIN; CHROMATIN MODIFICATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; EPIGENETICS; GENOMIC INSTABILITY; HEART AMYLOIDOSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE TELOMERE LENGTH; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PULSE PRESSURE; REVIEW; SARCOPENIA; SENESCENCE; SYSTOLIC HYPERTENSION; TELOMERE LENGTH; AGED; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; METABOLISM; PHYSIOLOGY;

AGED; AGING; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE MANAGEMENT; HUMANS;

EID: 85017318615     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.01.064     Document Type: Review

References (158)

1. 1 North, B.J., Sinclair, D.A., The intersection between aging and cardiovascular disease. Circ Res 110 (2012), 1097–1108.
2. 2 Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
3. 3 Fleg, J.L., Aronow, W.S., Frishman, W.H., Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 8 (2011), 13–28.
4. 4 Christensen, K., Doblhammer, G., Rau, R., et al. Ageing populations: the challenges ahead. Lancet 374 (2009), 1196–1208.
5. 5 Freedman, V.A., Martin, L.G., Schoeni, R.F., Recent trends in disability and functioning among older adults in the United States: a systematic review. JAMA 288 (2002), 3137–3146.
6. 6 Kovacic, J.C., Moreno, P., Nabel, E.G., et al. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation 123 (2011), 1900–1910.
7. 7 Kuller, L.H., Lopez, O.L., Mackey, R.H., et al. Subclinical cardiovascular disease and death, dementia, and coronary heart disease in patients 80+ years. J Am Coll Cardiol 67 (2016), 1013–1022.
8. 8 Newman, A.B., Naydeck, B.L., Ives, D.G., et al. Coronary artery calcium, carotid artery wall thickness, and cardiovascular disease outcomes in adults 70 to 99 years old. Am J Cardiol 101 (2008), 186–192.
9. 9 Camici, G.G., Savarese, G., Akhmedov, A., et al. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J 36 (2015), 3392–3403.
10. 10 Afilalo, J., Karunananthan, S., Eisenberg, M.J., et al. Role of frailty in patients with cardiovascular disease. Am J Cardiol 103 (2009), 1616–1621.
11. 11 Zieman, S.J., Melenovsky, V., Kass, D.A., Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005), 932–943.
12. 12 McEniery, C.M., Wilkinson, I.B., Avolio, A.P., Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 34 (2007), 665–671.
13. 13 Franklin, S.S., Khan, S.A., Wong, N.D., et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 100 (1999), 354–360.
14. 14 Franklin, S.S., Jacobs, M.J., Wong, N.D., et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37 (2001), 869–874.
15. 15 Chobanian, A.V., Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med 357 (2007), 789–796.
16. 16 Staessen, J.A., Gasowski, J., Wang, J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials [Published correction appears in Lancet 2001;357:724]. Lancet 355 (2000), 865–872.
17. 17 Appel, L.J., Espeland, M.A., Easter, L., et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 161 (2001), 685–693.
18. 18 Cook, N.R., Appel, L.J., Whelton, P.K., Sodium intake and all-cause mortality over 20 years in the Trials of Hypertension Prevention. J Am Coll Cardiol 68 (2016), 1609–1617.
19. 19 Messerli, F.H., Mancia, G., Conti, C.R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006), 884–893.
20. 20 Vidal-Petiot, E., Ford, I., Greenlaw, N., et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 388 (2016), 2142–2152.
21. 21 Selvaraj, S., Steg, P.G., Elbez, Y., et al., REACH Registry Investigators. Pulse pressure and risk for cardiovascular events in patients with atherothrombosis: from the REACH Registry. J Am Coll Cardiol 67 (2016), 392–403.
22. 22 McEvoy, J.W., Chen, Y., Rawlings, A., et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol 68 (2016), 1713–1722.
23. 23 Beckett, N.S., Peters, R., Fletcher, A.E., et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898.
24. 24 Williamson, J.D., Supiano, M.A., Applegate, W.B., et al., SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 315 (2016), 2673–2682.
25. 25 Bhatt, D.L., Troponin and the J-curve of diastolic blood pressure: when lower is not better. J Am Coll Cardiol 68 (2016), 1723–1726.
26. 26 Fuster, V., No such thing as ideal blood pressure: a case for personalized medicine. J Am Coll Cardiol 67 (2016), 3014–3015.
27. 27 Forette, F., Seux, M.L., Staessen, J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998), 1347–1351.
28. 28 Peila, R., White, L.R., Masaki, K., et al. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37 (2006), 1165–1170.
29. 29 Di Bari, M., Pahor, M., Franse, L.V., et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 153 (2001), 72–78.
30. 30 Wilson, P.W., D'Agostino, R.B., Levy, D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998), 1837–1847.
31. 31 Vita, J.A., Treasure, C.B., Nabel, E.G., et al. Coronary vasomotor response to acetylcholine relates to risk-factors for coronary-artery disease. Circulation 81 (1990), 491–497.
32. 32 Celermajer, D.S., Sorensen, K.E., Spiegelhalter, D.J., et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24 (1994), 471–476.
33. 33 Delp, M.D., Behnke, B.J., Spier, S.A., et al. Ageing diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles. J Physiol 586 (2008), 1161–1168.
34. 34 van der Loo, B., Labugger, R., Skepper, J.N., et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192 (2000), 1731–1744.
35. 35 Donato, A.J., Eskurza, I., Silver, A.E., et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-κB. Circ Res 100 (2007), 1659–1666.
36. 36 Lakatta, E.G., Levy, D., Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation 107 (2003), 139–146.
37. 37 Tschudi, M.R., Barton, M., Bersinger, N.A., et al. Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest 98 (1996), 899–905.
38. 38 Taddei, S., Virdis, A., Ghiadoni, L., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 38 (2001), 274–279.
39. 39 Lüscher, T.F., Yang, Z.H., Diederich, D., et al. Endothelium-derived vasoactive substances: potential role in hypertension, atherosclerosis, and vascular occlusion. J Cardiovasc Pharmacol 14:Suppl 6 (1989), S63–S69.
40. 40 Donato, A.J., Gano, L.B., Eskurza, I., et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 297 (2009), H425–H432.
41. 41 Durrant, J.R., Seals, D.R., Connell, M.L., et al. Voluntary wheel running restores endothelial function in conduit arteries of old mice: direct evidence for reduced oxidative stress, increased superoxide dismutase activity and down-regulation of NADPH oxidase. J Physiol 587 (2009), 3271–3285.
42. 42 Yang, Y.M., Huang, A., Kaley, G., et al. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 297 (2009), H1829–H1836.
43. 43 Santhanam, L., Christianson, D.W., Nyhan, D., et al. Arginase and vascular aging. J Appl Physiol (1985) 105 (2008), 1632–1642.
44. 44 Dikalov, S.I., Nazarewicz, R.R., Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxidants Redox Signaling 19 (2013), 1085–1094.
45. 45 Ungvari, Z., Orosz, Z., Labinskyy, N., et al. Increased mitochondrial H2O2 production promotes endothelial NF-κB activation in aged rat arteries. Am J Physiol Heart Circ Physiol 293 (2007), H37–H47.
46. 46 Van Guilder, G.P., Westby, C.M., Greiner, J.J., et al. Endothelin-1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic exercise. Hypertension 50 (2007), 403–409.
47. 47 Tang, E.H.C., Vanhoutte, P.M., Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 32 (2008), 409–418.
48. 48 Heymes, C., Habib, A., Yang, D., et al. Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 131 (2000), 804–810.
49. 49 Singh, N., Prasad, S., Singer, D., et al. Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. Clin Sci (Lond) 102 (2002), 595–600.
50. 50 Küng, C.F., Lüscher, T.F., Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 25 (1995), 194–200.
51. 51 Camici, G.G., Sudano, I., Noll, G., et al. Molecular pathways of aging and hypertension. Curr Opin Nephrol Hypertens 18 (2009), 134–137.
52. 52 Meyer, M.L., Tanaka, H., Palta, P., et al. Correlates of segmental pulse wave velocity in older adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens 29 (2016), 114–122.
53. 53 Fritze, O., Romero, B., Schleicher, M., et al. Age-related changes in the elastic tissue of the human aorta. J Vasc Res 49 (2012), 77–86.
54. 54 Liu, J., Sukhova, G.K., Sun, J.S., et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004), 1359–1366.
55. 55 Li, Z., Froehlich, J., Galis, Z.S., et al. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 33 (1999), 116–123.
56. 56 Aronson, D., Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21 (2003), 3–12.
57. 57 Amento, E.P., Ehsani, N., Palmer, H., et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11 (1991), 1223–1230.
58. 58 Huang, W., Alhenc Gelas, F., Osborne-Pellegrin, M.J., Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat. Circ Res 82 (1998), 879–890.
59. 59 Janić, M., Lunder, M., Šabovič, M., Arterial stiffness and cardiovascular therapy. Biomed Res Int, 2014, 2014, 621437.
60. 60 Walker, A.E., Henson, G.D., Reihl, K.D., et al. Greater impairments in cerebral artery compared with skeletal muscle feed artery endothelial function in a mouse model of increased large artery stiffness. J Physiol 593 (2015), 1931–1943.
61. 61 Isabelle, M., Simonet, S., Ragonnet, C., et al. Chronic reduction of nitric oxide level in adult spontaneously hypertensive rats induces aortic stiffness similar to old spontaneously hypertensive rats. J Vasc Res 49 (2012), 309–318.
62. 62 Lloyd-Jones, D.M., Larson, M.G., Leip, E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002), 3068–3072.
63. 63 Redfield, M.M., Heart failure with preserved ejection fraction. N Engl J Med 375 (2016), 1868–1877.
64. 64 Owan, T.E., Hodge, D.O., Herges, R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
65. 65 McMurray, J.J., Packer, M., Desai, A.S., et al., PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
66. 66 Otto, C.M., Prendergast, B., Aortic-valve stenosis—from patients at risk to severe valve obstruction. N Engl J Med 371 (2014), 744–756.
67. 67 Thanassoulis, G., Campbell, C.Y., Owens, D.S., et al., CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368 (2013), 503–512.
68. 68 Libby, P., How does lipid lowering prevent coronary events? New insights from human imaging trials. Eur Heart J 36 (2015), 472–474.
69. 69 Henein, M., Granåsen, G., Wiklund, U., et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol 184 (2015), 581–586.
70. 70 Falk, R.H., Diagnosis and management of the cardiac amyloidoses. Circulation 112 (2005), 2047–2060.
71. 71 González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
72. 72 Falk, R.H., Pondering the prognosis and pathology of cardiac amyloidosis: answers breed questions. J Am Coll Cardiol Img 9 (2016), 139–141.
73. 73 Rosenberg, I.H., Sarcopenia: origins and clinical relevance. J Nutr 127 (1997), 990S–991S.
74. 74 Curtis, E., Litwic, A., Cooper, C., et al. Determinants of muscle and bone aging. J Cell Physiol 230 (2015), 2618–2625.
75. 75 Reginster, J.Y., Beaudart, C., Buckinx, F., et al. Osteoporosis and sarcopenia: two diseases or one?. Curr Opin Clin Nutr Metab Care 19 (2016), 31–36.
76. 76 Calado, R.T., Young, N.S., Telomere diseases. N Engl J Med 361 (2009), 2353–2365.
77. 77 Kurz, D.J., Kloeckener-Gruissem, B., Akhmedov, A., et al. Degenerative aortic valve stenosis, but not coronary disease, is associated with shorter telomere length in the elderly. Arterioscler Thromb Vasc Biol 26 (2006), e114–e117.
78. 78 Brouilette, S.W., Moore, J.S., McMahon, A.D., et al., West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369 (2007), 107–114.
79. 79 Zhang, W., Chen, Y., Wang, Y., et al. Short telomere length in blood leucocytes contributes to the presence of atherothrombotic stroke and haemorrhagic stroke and risk of post-stroke death. Clin Sci (Lond) 125 (2013), 27–36.
80. 80 Chen, S., Lin, J., Matsuguchi, T., et al. Short leukocyte telomere length predicts incidence and progression of carotid atherosclerosis in American Indians: the Strong Heart Family Study. Aging (Albany NY) 6 (2014), 414–427.
81. 81 Haycock, P.C., Heydon, E.E., Kaptoge, S., et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ, 349, 2014, g4227.
82. 82 Kornfeld, O.S., Hwang, S., Disatnik, M.H., et al. Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases. Circ Res 116 (2015), 1783–1799.
83. 83 Cosentino, F., Francia, P., Camici, G.G., et al. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol 28 (2008), 622–628.
84. 84 Migliaccio, E., Giorgio, M., Mele, S., et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402 (1999), 309–313.
85. 85 Francia, P., delli Gatti, C., Bachschmid, M., et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 110 (2004), 2889–2895.
86. 86 Shi, Y., Savarese, G., Perrone-Filardi, P., et al. Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc. Int J Cardiol 175 (2014), 446–450.
87. 87 Spescha, R.D., Shi, Y., Wegener, S., et al. Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. Eur Heart J 34 (2013), 96–103.
88. 88 Spescha, R.D., Klohs, J., Semerano, A., et al. Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke. Eur Heart J 36 (2015), 1590–1600.
89. 89 Franzeck, F.C., Hof, D., Spescha, R.D., et al. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 220 (2012), 282–286.
90. 90 Pagnin, E., Fadini, G., de Toni, R., et al. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J Clin Endocrinol Metab 90 (2005), 1130–1136.
91. 91 Hernandez, J.M., Floyd, D.H., Weilbaecher, K.N., et al. Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 27 (2008), 4757–4767.
92. 92 Gerald, D., Berra, E., Frapart, Y.M., et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118 (2004), 781–794.
93. 93 Paneni, F., Osto, E., Costantino, S., et al. Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation 127 (2013), 1229–1240 e1–21.
94. 94 Ricci, R., Eriksson, U., Oudit, G.Y., et al. Distinct functions of junD in cardiac hypertrophy and heart failure. Genes Dev 19 (2005), 208–213.
95. 95 Thompson, A.M., Wagner, R., Rzucidlo, E.M., Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function. Am J Physiol Heart Circ Physiol 307 (2014), H533–H541.
96. 96 Zhang, Q.J., Wang, Z., Chen, H.Z., et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 80 (2008), 191–199.
97. 97 Stein, S., Lohmann, C., Schäfer, N., et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 31 (2010), 2301–2309.
98. 98 Miranda, M.X., van Tits, L.J., Lohmann, C., et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J 36 (2015), 51–59.
99. 99 Ota, H., Eto, M., Ako, J., et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol 53 (2009), 2298–2305.
100. 100 Ota, H., Akishita, M., Eto, M., et al. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 43 (2007), 571–579.
101. 101 Menghini, R., Casagrande, V., Cardellini, M., et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 120 (2009), 1524–1532.
102. 102 Zhou, S., Chen, H.Z., Wan, Y.Z., et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 109 (2011), 639–648.
103. 103 Winnik, S., Auwerx, J., Sinclair, D.A., et al. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 36 (2015), 3404–3412.
104. 104 Brunet, A., Sweeney, L.B., Sturgill, J.F., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004), 2011–2015.
105. 105 Mattagajasingh, I., Kim, C.S., Naqvi, A., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 104 (2007), 14855–14860.
106. 106 Martín-Núñez, E., Donate-Correa, J., Muros-de-Fuentes, M., et al. Implications of Klotho in vascular health and disease. World J Cardiol 6 (2014), 1262–1269.
107. 107 Ding, H.Y., Ma, H.X., Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease. J Geriatr Cardiol 12 (2015), 439–447.
108. 108 Lindberg, K., Olauson, H., Amin, R., et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One, 8, 2013, e60658.
109. 109 Kurosu, H., Yamamoto, M., Clark, J.D., et al. Suppression of aging in mice by the hormone Klotho. Science 309 (2005), 1829–1833.
110. 110 Lord, C.J., Ashworth, A., The DNA damage response and cancer therapy. Nature 481 (2012), 287–294.
111. 111 Vijg, J., Suh, Y., Genome instability and aging. Annu Rev Physiol 75 (2013), 645–668.
112. 112 Busuttil, R.A., Dollé, M., Campisi, J., et al. Genomic instability, aging, and cellular senescence. Ann N Y Acad Sci 1019 (2004), 245–255.
113. 113 Capell, B.C., Collins, F.S., Nabel, E.G., Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 101 (2007), 13–26.
114. 114 Durik, M., Kavousi, M., van der Pluijm, I., et al. Nucleotide excision DNA repair is associated with age-related vascular dysfunction. Circulation 126 (2012), 468–478.
115. 115 Shah, N.R., Mahmoudi, M., The role of DNA damage and repair in atherosclerosis: a review. J Mol Cell Cardiol 86 (2015), 147–157.
116. 116 Mahmoudi, M., Mercer, J., Bennett, M., DNA damage and repair in atherosclerosis. Cardiovasc Res 71 (2006), 259–268.
117. 117 Botto, N., Rizza, A., Colombo, M.G., et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 493 (2001), 23–30.
118. 118 Bautista Niño, P.K., Durik, M., Danser, A.H., et al. Phosphodiesterase 1 regulation is a key mechanism in vascular aging. Clin Sci (Lond) 129 (2015), 1061–1075.
119. 119 Jaiswal, S., Fontanillas, P., Flannick, J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
120. 120 Costantino, S., Paneni, F., Cosentino, F., Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. Curr Pharm Biotechnol 16 (2015), 531–543.
121. 121 Paneni, F., Costantino, S., Volpe, M., et al. Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis 230 (2013), 191–197.
122. 122 Singhal, R.P., Mays-Hoopes, L.L., Eichhorn, G.L., DNA methylation in aging of mice. Mech Ageing Dev 41 (1987), 199–210.
123. 123 Bollati, V., Schwartz, J., Wright, R., et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev 130 (2009), 234–239.
124. 124 Wang, J.C., Bennett, M., Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111 (2012), 245–259.
125. 125 Illi, B., Ciarapica, R., Capogrossi, M.C., Chromatin methylation and cardiovascular aging. J Mol Cell Cardiol 83 (2015), 21–31.
126. 126 López-Otín, C., Blasco, M.A., Partridge, L., et al. The hallmarks of aging. Cell 153 (2013), 1194–1217.
127. 127 Brunet, A., Berger, S.L., Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci 69:Suppl 1 (2014), S17–S20.
128. 128 Hasegawa, Y., Saito, T., Ogihara, T., et al. Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation 125 (2012), 1122–1133.
129. 129 Schones, D.E., Leung, A., Natarajan, R., Chromatin modifications associated with diabetes and obesity. Arterioscler Thromb Vasc Biol 35 (2015), 1557–1561.
130. 130 Paneni, F., Volpe, M., Lüscher, T.F., et al. SIRT1, p66Shc, and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes 62 (2013), 1800–1807.
131. 131 Paneni, F., Costantino, S., Battista, R., et al. Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. Circ Cardiovasc Genet 8 (2015), 150–158.
132. 132 Xu, S., Yin, M., Koroleva, M., et al. SIRT6 protects against endothelial dysfunction and atherosclerosis in mice. Aging (Albany NY) 8 (2016), 1064–1082.
133. 133 Lähteenvuo, J., Rosenzweig, A., Effects of aging on angiogenesis. Circ Res 110 (2012), 1252–1264.
134. 134 Zhang, H., van Olden, C., Sweeney, D., et al. Blood vessel repair and regeneration in the ischaemic heart. Open Heart, 1, 2014, e000016.
135. 135 Groen, B.B., Hamer, H.M., Snijders, T., et al. Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. J Appl Physiol (1985) 116 (2014), 998–1005.
136. 136 Creager, M.A., Olin, J.W., Belch, J.J., et al. Effect of hypoxia-inducible factor-1α gene therapy on walking performance in patients with intermittent claudication. Circulation 124 (2011), 1765–1773.
137. 137 Rajagopalan, S., Olin, J., Deitcher, S., et al. Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 115 (2007), 1234–1243.
138. 138 Goodell, M.A., Rando, T.A., Stem cells and healthy aging. Science 350 (2015), 1199–1204.
139. 139 Fadini, G.P., Losordo, D., Dimmeler, S., Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110 (2012), 624–637.
140. 140 Williamson, K., Stringer, S.E., Alexander, M.Y., Endothelial progenitor cells enter the aging arena. Front Physiol, 3, 2012, 30.
141. 141 Kushner, E.J., MacEneaney, O.J., Weil, B.R., et al. Aging is associated with a proapoptotic endothelial progenitor cell phenotype. J Vasc Res 48 (2011), 408–414.
142. 142 Murasawa, S., Llevadot, J., Silver, M., et al. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 106 (2002), 1133–1139.
143. 143 He, T., Joyner, M.J., Katusic, Z.S., Aging decreases expression and activity of glutathione peroxidase-1 in human endothelial progenitor cells. Microvasc Res 78 (2009), 447–452.
144. 144 Endtmann, C., Ebrahimian, T., Czech, T., et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 58 (2011), 394–403.
145. 145 Krankel, N., Luscher, T.F., Landmesser, U., Novel insights into vascular repair mechanisms. Curr Pharm Des 20 (2014), 2430–2438.
146. 146 Paneni, F., Costantino, S., Kränkel, N., et al. Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. Eur Heart J 37 (2016), 1733–1737.
147. 147 Mocharla, P., Briand, S., Giannotti, G., et al. AngiomiR-126 expression and secretion from circulating CD34+and CD14+ PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 121 (2013), 226–236.
148. 148 Zhu, S., Deng, S., Ma, Q., et al. MicroRNA-10A* and microRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2. Circ Res 112 (2013), 152–164.
149. 149 Zhao, T., Li, J., Chen, A.F., MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab 299 (2010), E110–E116.
150. 150 Gyöngyösi, M., Wojakowski, W., Lemarchand, P., et al., ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 116 (2015), 1346–1360.
151. 151 Quyyumi, A.A., Vasquez, A., Kereiakes, D., et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res 120 (2017), 324–331.
152. 152 Sürder, D., Manka, R., Moccetti, T., et al. Effect of bone marrow-derived mononuclear cell treatment, early or late after acute myocardial infarction: twelve months CMR and long-term clinical results. Circ Res 119 (2016), 481–490.
153. 153 Khan, A.R., Farid, T.A., Pathan, A., et al. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res 118 (2016), 984–993.
154. 154 Rapola, J.M., Virtamo, J., Ripatti, S., et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349 (1997), 1715–1720.
155. 155 Jarski, R.W., Hightower, K.R., Dangovian, M.I., Vitamin E supplementation, cardiovascular events, and cancer. JAMA 294 (2005), 425–426 author reply 426.
156. 156 Coletta, A.P., Clark, A.L., Banarjee, P., et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 4 (2002), 559–561.
157. 157 Venkatasubramanian, S., Noh, R.M., Daga, S., et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc, 2, 2013, e000042.
158. 158 Ungvari, Z., Parrado-Fernandez, C., Csiszar, A., et al. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res 102 (2008), 519–528.